BASEL, Switzerland and LONDON and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (“Roivant”) today announced that the members of the Board of Directors of Arbutus Biopharma ...

Roivant Sciences portfolio company Genevant Sciences and Canada’s Arbutus Biopharma yesterday filed five international ...

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic ...

All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. The virology-focused biotech company said Tuesday that ...

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Other equities ...

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus” or the "Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

(RTTNews) - Biopharmaceutical company Arbutus Biopharma Corp. (ABUS) announced Tuesday changes to its board of directors and the appointment of Lindsay Androski as Chief Executive Officer.

BASEL, Switzerland and LONDON and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) — Roivant Sciences Ltd. (“Roivant”) today announced that the members of the Board of Directors of Arbutus Biopharma ...

Genevant Sciences and Arbutus Biopharma (ABUS) filed five international lawsuits seeking to enforce patents protecting their innovative LNP ...